Allworth Financial
GTBP icon

Allworth Financial’s GT Biopharma GTBP Stock Holding History

Allworth Financial’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21K Hold
180
– – ﹤0.01% 4472
2026
Q1 		$1.84K Buy
+180
New +$2.46K ﹤0.01% 4376
2025
Q4 		– Hold
0
– – – 5001
2025
Q3 		– Hold
0
– – – 4909
2025
Q2 		– Hold
0
– – – 4577
2025
Q1 		– Hold
0
– – – 4045
2024
Q4 		– Hold
0
– – – 3923

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HRT Financial
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
Arax Advisory Partners
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $479M AUM 15.43% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Allworth Financial's GTBP Position: Q2 2026 in Review

Allworth Financial held its GT Biopharma (GTBP) position steady in Q2 2026 at 180 shares worth $2.21K. The position accounts for ﹤0.01% of the portfolio, ranked #4472.

Allworth Financial first reported a position in GTBP in Q1 2026 and has held it in 2 quarters since. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Allworth Financial held 180 shares of GT Biopharma worth $2.21K as of Q2 2026.
  • Allworth Financial left its GT Biopharma share count unchanged in Q2 2026.
  • GT Biopharma made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4472 holding.
  • Allworth Financial first reported a position in GT Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.